WallStSmart

Elevance Health Inc (ELV)vsThermo Fisher Scientific Inc (TMO)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Elevance Health Inc generates 343% more annual revenue ($200.42B vs $45.20B). TMO leads profitability with a 15.1% profit margin vs 2.6%. ELV appears more attractively valued with a PEG of 1.43. TMO earns a higher WallStSmart Score of 62/100 (C+).

ELV

Buy

56

out of 100

Grade: C

Growth: 4.0Profit: 5.5Value: 8.0Quality: 5.0
Piotroski: 3/9

TMO

Buy

62

out of 100

Grade: C+

Growth: 4.7Profit: 7.0Value: 4.7Quality: 5.3
Piotroski: 3/9
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ELVUndervalued (+63.5%)

Margin of Safety

+63.5%

Fair Value

$1011.48

Current Price

$374.71

$636.77 discount

UndervaluedFair: $1011.48Overvalued
TMOOvervalued (-14.2%)

Margin of Safety

-14.2%

Fair Value

$408.60

Current Price

$472.95

$64.35 premium

UndervaluedFair: $408.60Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ELV4 strengths · Avg: 8.3/10
Market CapQuality
$80.93B9/10

Large-cap with strong market position

P/E RatioValuation
15.8x8/10

Attractively priced relative to earnings

Price/BookValuation
1.9x8/10

Reasonable price relative to book value

Free Cash FlowQuality
$4.10B8/10

Generating 4.1B in free cash flow

TMO1 strengths · Avg: 9.0/10
Market CapQuality
$174.37B9/10

Large-cap with strong market position

Areas to Watch

ELV4 concerns · Avg: 3.0/10
Revenue GrowthGrowth
2.6%4/10

2.6% revenue growth

Profit MarginProfitability
2.6%3/10

2.6% margin — thin

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

EPS GrowthGrowth
-16.8%2/10

Earnings declined 16.8%

TMO3 concerns · Avg: 3.7/10
PEG RatioValuation
1.544/10

Expensive relative to growth rate

P/E RatioValuation
25.8x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : ELV

The strongest argument for ELV centers on Market Cap, P/E Ratio, Price/Book. PEG of 1.43 suggests the stock is reasonably priced for its growth.

Bull Case : TMO

The strongest argument for TMO centers on Market Cap. Profitability is solid with margins at 15.1% and operating margin at 17.9%.

Bear Case : ELV

The primary concerns for ELV are Revenue Growth, Profit Margin, Piotroski F-Score. Thin 2.6% margins leave little buffer for downturns.

Bear Case : TMO

The primary concerns for TMO are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

ELV profiles as a value stock while TMO is a mature play — different risk/reward profiles.

TMO carries more volatility with a beta of 0.97 — expect wider price swings.

TMO is growing revenue faster at 6.2% — sustainability is the question.

ELV generates stronger free cash flow (4.1B), providing more financial flexibility.

Bottom Line

TMO scores higher overall (62/100 vs 56/100), backed by strong 15.1% margins. ELV offers better value entry with a 63.5% margin of safety. Both earn "Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Elevance Health Inc

HEALTHCARE · HEALTHCARE PLANS · USA

Elevance Health Inc. is a health benefits company. The company is headquartered in Indianapolis, Indiana.

Thermo Fisher Scientific Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Thermo Fisher Scientific is an American provisioner of scientific instrumentation, reagents and consumables, and software and services to healthcare, life science, and other laboratories in academia, government, and industry (including in the biotechnology and pharmaceutical sectors). Based in Waltham, Massachusetts, Thermo Fisher was created in 2006 by the merger of Thermo Electron and Fisher Scientific, to form a company with US$ 9 billion in combined revenues.

Visit Website →

Want to dig deeper into these stocks?